跳至主要内容
临床试验/JPRN-UMIN000003680
JPRN-UMIN000003680已完成2 期

Phase II study of Pemetrexed and Carboplatin plus Bevacizumab for advanced non-small cell lung cancer - Phase II study of Pemetrexed and Carboplatin plus Bevacizumab for advanced non-small cell lung cancer

ippon Medical School Hospital0 个研究点目标入组 26 人开始时间: 2010年6月3日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
26

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 75years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1)Uncontrolled infection or serious medical complications 2)massive pleural effusion or ascites(accept controrable pleural effusion with OK-432) 3)brain metastasis 4)history of severe cardiac disease 5)uncontrollable diabetes 6)recieving anticoagulant drug(except Aspirin under 324mg/day) 7)history of gross hemoptysis(>2.6ml) 8)history of severe hemosputum(over 1week, or reciving hemostatic drug) 9)uncontrollable hypertension 10)history of GI perfortion(within the last 1 year) 11)history of myocardial infarction or cerebral infarction 12)interstitial pneumonia or pulmonary fibrosis detectable on CT scan 13)history of drug-indused pneumonitis 14)the operation has been scheduled for the examination period 15)treatment history of Pemetrexed, Carboplatin, and Bevacizumab 16)severe drug allegy 17)not reciving folic acid and vitamin B12 18)active concomitant malignancy 19)history of severe mental disorder 20)now pregnant or lactation 21)judged to be not suitable by the attending physician

研究者

发起方
ippon Medical School Hospital

相似试验